We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
- Authors
Sharma, Anupama; Koldovsky, Ursula; Xu, Shuwen; Mick, Rosemarie; Roses, Robert; Fitzpatrick, Elizabeth; Weinstein, Susan; Nisenbaum, Harvey; Levine, Bruce L.; Fox, Kevin; Zhang, Paul; Koski, Gary; Czerniecki, Brian J.
- Abstract
BACKGROUND: HER-2/ neu overexpression plays a critical role in breast cancer development, and its expression in ductal carcinoma in situ (DCIS) is associated with development of invasive breast cancer. A vaccine targeting HER-2/ neu expression in DCIS may initiate immunity against invasive cancer. METHODS: A HER-2/ neu dendritic cell vaccine was administered to 27 patients with HER-2/ neu-overexpressing DCIS. The HER-2/ neu vaccine was administered before surgical resection, and pre- and postvaccination analysis was conducted to assess clinical results. RESULTS: At surgery, 5 of 27 (18.5%) vaccinated subjects had no evidence of remaining disease, whereas among 22 subjects with residual DCIS, HER-2/ neu expression was eradicated in 11 (50%). When comparing estrogen receptor (ER)neg with ERpos DCIS lesions, vaccination was more effective in hormone-independent DCIS. After vaccination, no residual DCIS was found in 40% of ERneg subjects compared with 5.9% in ERpos subjects. Sustained HER-2/ neu expression was found in 10% of ERneg subjects compared with 47.1% in ERpos subjects ( P = .04). Postvaccination phenotypes were significantly different between ERpos and ERneg subjects ( P = .01), with 7 of 16 (43.8%) initially presenting with ERposHER-2/ neupos luminal B phenotype finishing with the ERposHER-2/ neuneg luminal A phenotype, and 3 of 6 (50%) with the ERnegHER-2/ neupos phenotype changing to the ERnegHER-2/ neuneg phenotype. CONCLUSIONS: Results suggest that vaccination against HER-2/ neu is safe and well tolerated and induces decline and/or eradication of HER-2/ neu expression. These findings warrant further exploration of HER-2/ neu vaccination in estrogen-independent breast cancer and highlight the need to target additional tumor-associated antigens and pathways. Cancer 2012. © 2012 American Cancer Society.
- Subjects
HER2 gene; DENDRITIC cells; BREAST cancer vaccines; CANCER vaccines; GENE expression; DUCTAL carcinoma; ESTROGEN receptors
- Publication
Cancer (0008543X), 2012, Vol 118, Issue 17, p4354
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.26734